Collegium Reports Definitive Agreement to Acquire BioDelivery Sciences
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) and BioDelivery Sciences International Inc. (NASDAQ: BDSI) have announced a definitive agreement where Collegium will acquire BDSI for USD 5.60 per share in cash. BDSI holds a portfolio of pain and neurology products that focus on serious and debilitating conditions. “We are excited to announce this acquisition, which represents a …
Collegium Reports Definitive Agreement to Acquire BioDelivery Sciences Read More »